Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Fibroblast growth factor receptor 3 interacts with and activates TGFβ-activated kinase 1 tyrosine phosphorylation and NFκB signaling in multiple myeloma and bladder cancer.

Salazar L, Kashiwada T, Krejci P, Meyer AN, Casale M, Hallowell M, Wilcox WR, Donoghue DJ, Thompson LM.

PLoS One. 2014 Jan 23;9(1):e86470. doi: 10.1371/journal.pone.0086470.

2.

FGFR3 stimulates stearoyl CoA desaturase 1 activity to promote bladder tumor growth.

Du X, Wang QR, Chan E, Merchant M, Liu J, French D, Ashkenazi A, Qing J.

Cancer Res. 2012 Nov 15;72(22):5843-55. doi: 10.1158/0008-5472.CAN-12-1329.

3.

Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.

Qing J, Du X, Chen Y, Chan P, Li H, Wu P, Marsters S, Stawicki S, Tien J, Totpal K, Ross S, Stinson S, Dornan D, French D, Wang QR, Stephan JP, Wu Y, Wiesmann C, Ashkenazi A.

J Clin Invest. 2009 May;119(5):1216-29. doi: 10.1172/JCI38017.

4.

LATS2 inhibits the activity of NF-κ B signaling by disrupting the interaction between TAK1 and IKKβ.

Yao F, Zhou W, Zhong C, Fang W.

Tumour Biol. 2015 Sep;36(10):7873-9. doi: 10.1007/s13277-015-3362-x.

PMID:
25946971
5.

TAB4 stimulates TAK1-TAB1 phosphorylation and binds polyubiquitin to direct signaling to NF-kappaB.

Prickett TD, Ninomiya-Tsuji J, Broglie P, Muratore-Schroeder TL, Shabanowitz J, Hunt DF, Brautigan DL.

J Biol Chem. 2008 Jul 11;283(28):19245-54. doi: 10.1074/jbc.M800943200.

6.

The receptor tyrosine kinase FGFR4 negatively regulates NF-kappaB signaling.

Drafahl KA, McAndrew CW, Meyer AN, Haas M, Donoghue DJ.

PLoS One. 2010 Dec 22;5(12):e14412. doi: 10.1371/journal.pone.0014412.

7.

Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis.

Plowright EE, Li Z, Bergsagel PL, Chesi M, Barber DL, Branch DR, Hawley RG, Stewart AK.

Blood. 2000 Feb 1;95(3):992-8.

8.

TAK1-ECSIT-TRAF6 complex plays a key role in the TLR4 signal to activate NF-κB.

Wi SM, Moon G, Kim J, Kim ST, Shim JH, Chun E, Lee KY.

J Biol Chem. 2014 Dec 19;289(51):35205-14. doi: 10.1074/jbc.M114.597187.

9.

Cross interference with TNF-alpha-induced TAK1 activation via EGFR-mediated p38 phosphorylation of TAK1-binding protein 1.

Shin MS, Shinghirunnusorn P, Sugishima Y, Nishimura M, Suzuki S, Koizumi K, Saiki I, Sakurai H.

Biochim Biophys Acta. 2009 Jul;1793(7):1156-64. doi: 10.1016/j.bbamcr.2009.04.005.

10.

Simultaneous blockade of NFkappaB, JNK, and p38 MAPK by a kinase-inactive mutant of the protein kinase TAK1 sensitizes cells to apoptosis and affects a distinct spectrum of tumor necrosis factor [corrected] target genes.

Thiefes A, Wolter S, Mushinski JF, Hoffmann E, Dittrich-Breiholz O, Graue N, Dörrie A, Schneider H, Wirth D, Luckow B, Resch K, Kracht M.

J Biol Chem. 2005 Jul 29;280(30):27728-41. Erratum in: J Biol Chem. 2005 Sep 16;280(37):32564.

11.

Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways.

Kobayashi T, Kuroda J, Ashihara E, Oomizu S, Terui Y, Taniyama A, Adachi S, Takagi T, Yamamoto M, Sasaki N, Horiike S, Hatake K, Yamauchi A, Hirashima M, Taniwaki M.

Leukemia. 2010 Apr;24(4):843-50. doi: 10.1038/leu.2010.25.

PMID:
20200560
12.

TNF-like weak inducer of apoptosis (TWEAK) activates proinflammatory signaling pathways and gene expression through the activation of TGF-beta-activated kinase 1.

Kumar M, Makonchuk DY, Li H, Mittal A, Kumar A.

J Immunol. 2009 Feb 15;182(4):2439-48. doi: 10.4049/jimmunol.0803357.

14.

TGF-beta coordinately activates TAK1/MEK/AKT/NFkB and SMAD pathways to promote osteoclast survival.

Gingery A, Bradley EW, Pederson L, Ruan M, Horwood NJ, Oursler MJ.

Exp Cell Res. 2008 Sep 10;314(15):2725-38. doi: 10.1016/j.yexcr.2008.06.006.

15.
16.

Nordihydroguaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells.

Meyer AN, McAndrew CW, Donoghue DJ.

Cancer Res. 2008 Sep 15;68(18):7362-70. doi: 10.1158/0008-5472.CAN-08-0575.

17.

Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer.

Hernandez L, Hsu SC, Davidson B, Birrer MJ, Kohn EC, Annunziata CM.

Cancer Res. 2010 May 15;70(10):4005-14. doi: 10.1158/0008-5472.CAN-09-3912.

18.

URGCP/URG4 promotes apoptotic resistance in bladder cancer cells by activating NF-κB signaling.

Wu M, Chen J, Wang Y, Hu J, Liu C, Feng C, Zeng X.

Oncotarget. 2015 Oct 13;6(31):30887-901. doi: 10.18632/oncotarget.5134.

19.

The cytoplasmic tyrosine kinase Pyk2 as a novel effector of fibroblast growth factor receptor 3 activation.

Meyer AN, Gastwirt RF, Schlaepfer DD, Donoghue DJ.

J Biol Chem. 2004 Jul 2;279(27):28450-7.

20.

Transient activation of NF-kappaB through a TAK1/IKK kinase pathway by TGF-beta1 inhibits AP-1/SMAD signaling and apoptosis: implications in liver tumor formation.

Arsura M, Panta GR, Bilyeu JD, Cavin LG, Sovak MA, Oliver AA, Factor V, Heuchel R, Mercurio F, Thorgeirsson SS, Sonenshein GE.

Oncogene. 2003 Jan 23;22(3):412-25.

PMID:
12545162

Supplemental Content

Support Center